Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis

Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy

Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359 · see citing works

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B

Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · see citing works

Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo

Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291 · see citing works

Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis

Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064 · see citing works

Diffusible, nonfibrillar ligands derived from Aβ _1–42 are potent central nervous system neurotoxins

Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506 · see citing works

Journal of Biological Chemistry

Kurkinensp, M., CondongT, M. R., Blumberg, B., Barlow, D. P., Quiñones, S., Sausg, J., & Pihlajaniemisyy, T. (2021) · Journal of Biological Chemistry · doi:10.1074/jbc · Cited by 3,409 · see citing works

Curcumin Inhibits Formation of Amyloid β Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo

Yang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336 · see citing works

The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes

Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962 · see citing works

High-Level Neuronal Expression of Aβ_1–42in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation

Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856 · see citing works

A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline

Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738 · see citing works

Natural oligomers of the amyloid-β protein specifically disrupt cognitive function

Cleary, J. P., Walsh, D. M., Hofmeister, J. J., Shankar, G. M., Kuskowski, M. A., Selkoe, D. J., & Ashe, K. H. (2004) · Nature Neuroscience · doi:10.1038/nn1372 · Cited by 1,677 · see citing works

Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers

Laurén, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., & Strittmatter, S. M. (2009) · Nature · doi:10.1038/nature07761 · Cited by 1,560 · see citing works

Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism

Cohen, S. I. A., Linse, S. S., Luheshi, L. M., Hellstrand, E., White, D. A., Rajah, L., Otzen, D. E., Vendruscolo, M., Dobson, C. M., & Knowles, T. P. J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218402110 · Cited by 1,410 · see citing works

Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment: A Pilot Clinical Trial

Craft, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.233 · Cited by 1,253 · see citing works

Aβ Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease

Lacor, P. N., Buniel, M. C., Furlow, P. W., Sanz Clemente, A., Velasco, P. T., Wood, M., Viola, K. L., & Klein, W. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3501-06.2007 · Cited by 1,188 · see citing works

Alzheimer’s disease is type 3 diabetes—Evidence reviewed

de la Monte, S. M., & Wands, J. R. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200619 · Cited by 1,158 · see citing works

Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss

Gong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A., & Klein, W. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834302100 · Cited by 1,061 · see citing works

Neurotoxicity of Amyloid  -Protein: Synaptic and Network Dysfunction

Mucke, L., & Selkoe, D. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006338 · Cited by 1,000 · see citing works

Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum?

Klein, W. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01749-5 · Cited by 989 · see citing works

Synaptic Targeting by Alzheimer's-Related Amyloid β Oligomers

Lacor, P. N., Buniel, M. C., Chang, L., Fernandez, S. J., Gong, Y., Viola, K. L., Lambert, M. P., Velasco, P. T., Bigio, E. H., Finch, C. E., et al. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3432-04.2004 · Cited by 954 · see citing works

Detection of a Biomarker for Alzheimer's Disease from Synthetic and Clinical Samples Using a Nanoscale Optical Biosensor

Haes, A. J., Chang, L., Klein, W. L., & Duyne, R. P. V. (2005) · Journal of the American Chemical Society · doi:10.1021/ja044087q · Cited by 866 · see citing works

Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model

Dodart, J.-C., Bales, K. R., Gannon, K. S., Greene, S. J., DeMattos, R. B., Mathis, C., DeLong, C. A., Wu, S., Wu, X., Holtzman, D. M., et al. (2002) · Nature Neuroscience · doi:10.1038/nn842 · Cited by 858 · see citing works

Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques

Koffie, R. M., Meyer-Luehmann, M., Hashimoto, T., Adams, K. W., Mielke, M. L., Garcia-Alloza, M., Micheva, K. D., Smith, S. J., Kim, M. L., Lee, V. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811698106 · Cited by 850 · see citing works

Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer’s disease

Georganopoulou, D. G., Chang, L., Nam, J.-M., Thaxton, C. S., Mufson, E. J., Klein, W. L., & Mirkin, C. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409336102 · Cited by 835 · see citing works

An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease–associated Aβ oligomers

Bomfim, T. R., Forny‐Germano, L., Sathler, L. B., Brito‐Moreira, J., Houzel, J., Decker, H., Silverman, M. A., Kazi, H., Melo, H. M., McClean, P. L., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci57256 · Cited by 830 · see citing works

Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers

Kayed, R., Head, E., Sarsoza, F., Saing, T., Cotman, C. W., Necula, M., Margol, L., Wu, J., Breydo, L., Thompson, J. L., et al. (2007) · Molecular Neurodegeneration · doi:10.1186/1750-1326-2-18 · Cited by 773 · see citing works

Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer’s disease brain contribute to neuronal death1

Allanbutterfield, D., Castegna, A., Lauderback, C. M., & Drake, J. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00340-2 · Cited by 715 · see citing works

Aβ Oligomers Cause Localized Ca ²⁺ Elevation, Missorting of Endogenous Tau into Dendrites, Tau Phosphorylation, and Destruction of Microtubules and Spines

Zempel, H., Thies, E., Mandelkow, E., & Mandelkow, E.-M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.2357-10.2010 · Cited by 686 · see citing works

Distinct α-Synuclein Strains Differentially Promote Tau Inclusions in Neurons

Guo, J. L., Covell, D. J., Daniels, J. P., Iba, M., Stieber, A., Zhang, B., Riddle, D. M., Kwong, L. K., Xu, Y., Trojanowski, J. Q., et al. (2013) · Cell · doi:10.1016/j.cell.2013.05.057 · Cited by 680 · see citing works

Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers

De Felice, F. G., Vieira, M. N. N., Bomfim, T. R., Decker, H., Velasco, P. T., Lambert, M. P., Viola, K. L., Zhao, W.-Q., Ferreira, S. T., & Klein, W. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809158106 · Cited by 657 · see citing works

Seeding of Normal Tau by Pathological Tau Conformers Drives Pathogenesis of Alzheimer-like Tangles

Guo, J. L., & Lee, V. M.-Y. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.209296 · Cited by 636 · see citing works

Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study

Siebner, H. R., Riemenschneider, M. J., Willoch, F., Minoshima, S., Schwaiger, M., Kurz, A., Drzezga, A. E., & Lautenschlager, N. T. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-003-1194-1 · Cited by 603 · see citing works

Amyloid beta oligomers induce impairment of neuronal insulin receptors

Zhao, W., De Felice, F. G., Fernandez, S., Chen, H., Lambert, M. P., Quon, M. J., Krafft, G. A., & Klein, W. L. (2008) · The FASEB Journal · doi:10.1096/fj.06-7703com · Cited by 587 · see citing works

Metabotropic Glutamate Receptor 5 Is a Coreceptor for Alzheimer Aβ Oligomer Bound to Cellular Prion Protein

Um, J. W., Kaufman, A. C., Kostylev, M., Heiss, J. K., Stagi, M., Takahashi, H., Kerrisk, M. E., Vortmeyer, A., Wisniewski, T., Koleske, A. J., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.06.036 · Cited by 572 · see citing works

Atomic View of a Toxic Amyloid Small Oligomer

Laganowsky, A. D., Liu, C., Sawaya, M. R., Whitelegge, J. P., Park, J., Zhao, M., Pensalfini, A., Soriaga, A. B., Landau, M., Teng, P. K., et al. (2012) · Science · doi:10.1126/science.1213151 · Cited by 564 · see citing works

Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus

Wang, H.-W., Pasternak, J. F., Kuo, H., Ristic, H., Lambert, M. P., Chromy, B., Viola, K. L., Klein, W. L., Stine, W. B., Krafft, G. A., et al. (2002) · Brain Research · doi:10.1016/s0006-8993(01)03058-x · Cited by 527 · see citing works

Self-Assembly of Aβ ₁ _- ₄₂ into Globular Neurotoxins

Chromy, B. A., Nowak, R. J., Lambert, M. P., Viola, K. L., Chang, L., Velasco, P. T., Jones, B. W., Fernandez, S. J., Lacor, P. N., Horowitz, P., et al. (2003) · Biochemistry · doi:10.1021/bi030029q · Cited by 522 · see citing works

Amyloid, hypometabolism, and cognition in Alzheimer disease: An [11C]PIB and [18F]FDG PET study

Edison, P., Archer, H. A., Hinz, R., Hammers, A., Pavese, N., Tai, Y. F., Hotton, G., Cutler, D., Fox, N., Kennedy, A., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000244749.20056.d4 · Cited by 518 · see citing works

The Oligomerization of Amyloid β-Protein Begins Intracellularly in Cells Derived from Human Brain

Walsh, D. M., Tseng, B. P., Rydel, R. E., Podlisny, M. B., & Selkoe, D. J. (2000) · Biochemistry · doi:10.1021/bi001048s · Cited by 502 · see citing works

Resolving controversies on the path to Alzheimer's therapeutics

Selkoe, D. J. (2011) · Nature Medicine · doi:10.1038/nm.2460 · Cited by 494 · see citing works

Deleterious Effects of Amyloid β Oligomers Acting as an Extracellular Scaffold for mGluR5

Renner, M., Lacor, P. N., Velasco, P. T., Xu, J., Contractor, A., Klein, W. L., & Triller, A. (2010) · Neuron · doi:10.1016/j.neuron.2010.04.029 · Cited by 468 · see citing works

The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease

Ferreira, S. T., & Klein, W. L. (2011) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2011.08.003 · Cited by 442 · see citing works

Environmental enrichment strengthens corticocortical interactions and reduces amyloid-β oligomers in aged mice

Mainardi, M., Garbo, A. D., Caleo, M., Berardi, N., Sale, A., & Maffei, L. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00001 · Cited by 438 · see citing works

Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers

De Felice, F. G., Wu, D., Lambert, M. P., Fernandez, S. J., Velasco, P. T., Lacor, P. N., Bigio, E. H., Jerecic, J., Acton, P. J., Shughrue, P. J., et al. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.02.029 · Cited by 432 · see citing works

Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β

Nussbaum, J. M., Schilling, S., Cynis, H., Silva, A., Swanson, E., Wangsanut, T., Tayler, K., Wiltgen, B., Hatami, A., Rönicke, R., et al. (2012) · Nature · doi:10.1038/nature11060 · Cited by 427 · see citing works

Prion protein recruits its neuronal receptor NCAM to lipid rafts to activate p59fyn and to enhance neurite outgrowth

Chadha, A. S., Sytnyk, V., Leshchyns’ka, I., & Schachner, M. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200409127 · Cited by 419 · see citing works

Molecular Mechanisms of Amyloid Oligomers Toxicity

Kayed, R., & Lasagna‐Reeves, C. A. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-129001 · Cited by 417 · see citing works

TNF-α Mediates PKR-Dependent Memory Impairment and Brain IRS-1 Inhibition Induced by Alzheimer’s β-Amyloid Oligomers in Mice and Monkeys

Lourenco, M. V., Clarke, J. R., Frozza, R. L., Bomfim, T. R., Forny‐Germano, L., Batista, A. F., Sathler, L. B., Brito‐Moreira, J., Amaral, O. B., Silva, C. A., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.11.002 · Cited by 415 · see citing works

Curcumin: an orally bioavailable blocker of TNF and other pro‐inflammatory biomarkers

Aggarwal, B. B., Gupta, S. C., & Sung, B. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12131 · Cited by 401 · see citing works

Parkinson's Disease and Alpha Synuclein: Is Parkinson's Disease a Prion‐Like Disorder?

Olanow, C. W., & Brundin, P. (2013) · Movement Disorders · doi:10.1002/mds.25373 · Cited by 392 · see citing works

Temporal Profile of Amyloid-β (Aβ) Oligomerization in an in Vivo Model of Alzheimer Disease

Oddo, S., Caccamo, A., Tran, L., Lambert, M. P., Glabe, C. G., Klein, W. L., & LaFerla, F. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m507892200 · Cited by 379 · see citing works

Polymorphism in the intermediates and products of amyloid assembly

Kodali, R. B., & Wetzel, R. B. (2007) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2007.01.007 · Cited by 376 · see citing works

Intraneuronal β-amyloid accumulation and synapse pathology in Alzheimer’s disease

Gouras, G. K., Tampellini, D., Takahashi, R. H., & Capetillo-Zarate, E. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0679-9 · Cited by 372 · see citing works

Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease

McClean, P. L., & Hölscher, C. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.08.005 · Cited by 359 · see citing works

Vaccination with soluble Aβ oligomers generates toxicity‐neutralizing antibodies

Lambert, M. P., Viola, K. L., Chromy, B. A., Chang, L., Morgan, T. E., Yu, J., Venton, D. L., Krafft, G. A., Finch, C. E., & Klein, W. L. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00592.x · Cited by 349 · see citing works

How does brain insulin resistance develop in Alzheimer's disease?

De Felice, F. G., Lourenco, M. V., & Ferreira, S. T. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.004 · Cited by 337 · see citing works

An Effector-Reduced Anti- -Amyloid (A ) Antibody with Unique A  Binding Properties Promotes Neuroprotection and Glial Engulfment of A

Adolfsson, O., Pihlgren, M., Toni, N., Varisco, Y., Buccarello, A. L., Antoniello, K., Lohmann, S., Piorkowska, K., Gafner, V., Atwal, J. K., et al. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.4742-11.2012 · Cited by 317 · see citing works

Monoclonal antibodies that target pathological assemblies of Aβ

Lambert, M. P., Velasco, P. T., Chang, L., Viola, K. L., Fernandez, S., Lacor, P. N., Khuon, D., Gong, Y., Bigio, E. H., Shaw, P., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04157.x · Cited by 314 · see citing works

Type 3 diabetes is sporadic Alzheimer׳s disease: Mini-review

de la Monte, S. M. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.06.008 · Cited by 312 · see citing works

Synaptic changes in Alzheimer’s disease and its models

Pozueta, J., Lefort, R., & Shelanski, M. L. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.05.050 · Cited by 305 · see citing works

Amyloid‐beta oligomerization in Alzheimer dementia versus high‐pathology controls

Esparza, T. J., Zhao, H., Cirrito, J. R., Cairns, N. J., Bateman, R. J., Holtzman, D. M., & Brody, D. L. (2012) · Annals of Neurology · doi:10.1002/ana.23748 · Cited by 304 · see citing works

Alzheimer's disease: synapses gone cold

Koffie, R. M., Hyman, B. T., & Spires‐Jones, T. L. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-63 · Cited by 302 · see citing works

Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers II: Sigma-2/PGRMC1 Receptors Mediate Abeta 42 Oligomer Binding and Synaptotoxicity

Izzo, N. J., Xu, J., Zeng, C., Kirk, M. J., Mozzoni, K., Silky, C., Rehak, C., Yurko, R., Look, G. C., Rishton, G. M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111899 · Cited by 294 · see citing works

Exercise counteracts declining hippocampal function in aging and Alzheimer's disease

Intlekofer, K. A., & Cotman, C. W. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.06.011 · Cited by 286 · see citing works

Amyloid β-protein oligomers and Alzheimer’s disease

Hayden, E. Y., & Teplow, D. B. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt226 · Cited by 276 · see citing works

The Murine Version of BAN2401 (mAb158) Selectively Reduces Amyloid-β Protofibrils in Brain and Cerebrospinal Fluid of tg-ArcSwe Mice

Tucker, S., Möller, C., Tegerstedt, K., Lord, A., Laudon, H., Sjödahl, J., Söderberg, L., Spens, E., Sahlin, C., Waara, E. R., et al. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-140741 · Cited by 272 · cited 1× · see citing works

Lost after translation: missorting of Tau protein and consequences for Alzheimer disease

Zempel, H., & Mandelkow�, E. (2014) · Trends in Neurosciences · doi:10.1016/j.tins.2014.08.004 · Cited by 272 · see citing works

Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology

McAlpine, F. E., Lee, J., Harms, A. S., Ruhn, K. A., Blurton-Jones, M. M., Hong, J. J., Das, P., Golde, T. E., LaFerla, F. M., Oddo, S., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.01.006 · Cited by 269 · see citing works

The Role of Stable α-Synuclein Oligomers in the Molecular Events Underlying Amyloid Formation

Lorenzen, N., Nielsen, S. B., Buell, A. K., Kaspersen, J. D., Arosio, P., Vad, B. S., Pasławski, W., Christiansen, G., Valnickova-Hansen, Z., Andreasen, M., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja411577t · Cited by 255 · see citing works

Targeting Amyloid-β Peptide (Aβ) Oligomers by Passive Immunization with a Conformation-selective Monoclonal Antibody Improves Learning and Memory in Aβ Precursor Protein (APP) Transgenic Mice

Lee, E. B., Leng, L. Z., Zhang, B., Kwong, L. K., Trojanowski, J. Q., Abel, T. G., & Lee, V. M. ‐. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m511018200 · Cited by 252 · see citing works

Spreading of Neurodegenerative Pathology via Neuron-to-Neuron Transmission of  -Amyloid

Nath, S., Agholme, L., Kurudenkandy, F. R., Granseth, B., Marcusson, J., & Hallbeck, M. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.0615-12.2012 · Cited by 244 · see citing works

Conformational Differences between Two Amyloid β Oligomers of Similar Size and Dissimilar Toxicity

Ladiwala, A. R. A., Litt, J., Kane, R. S., Aucoin, D., Smith, S. O., Ranjan, S., Davis, J., Nostrand, W. E. V., & Tessier, P. M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.329763 · Cited by 223 · see citing works

Chronic Neuron-Specific Tumor Necrosis Factor-Alpha Expression Enhances the Local Inflammatory Environment Ultimately Leading to Neuronal Death in 3xTg-AD Mice

Janelsins, M. C., Mastrangelo, M. A., Park, K. M., Sudol, K. L., Narrow, W. C., Oddo, S., LaFerla, F. M., Callahan, L. M., Federoff, H. J., & Bowers, W. J. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.080528 · Cited by 220 · see citing works

Decreased Brain-Derived Neurotrophic Factor Depends on Amyloid Aggregation State in Transgenic Mouse Models of Alzheimer's Disease

Peng, S., Garzon, D. J., Marchese, M., Klein, W. L., Ginsberg, S. D., Francis, B. M., Mount, H. T. J., Mufson, E. J., Salehi, A., & Fahnestock, M. L. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.4736-08.2009 · Cited by 216 · see citing works

Cross‐seeding effects of amyloid β‐protein and α‐synuclein

Ono, K., Takahashi, R., Ikeda, T., & Yamada, M. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07847.x · Cited by 213 · see citing works

Selective neuronal degeneration induced by soluble oligomeric amyloid beta‐protein

Kim, H., Chae, S., Lee, D., Chromy, B. A., Lee, S. C., Park, Y., Klein, W. L., Krafft, G. A., & Hong, S. (2002) · The FASEB Journal · doi:10.1096/fj.01-0987fje · Cited by 210 · see citing works

The secreted Wnt antagonist Dickkopf-1 is required for amyloid β-mediated synaptic loss

Purro, S. A., Dickins, E. M., & Salinas, P. C. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.4562-11.2012 · Cited by 195 · see citing works

Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid β After a Single Administration of an Amyloid β Monoclonal Antibody in Subjects With Alzheimer Disease

Siemers, E., Friedrich, S. W., Dean, R. A., Gonzales, C., Farlow, M. R., Paul, S. M., & Demattos, R. B. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181cb577a · Cited by 192 · see citing works

Towards non-invasive diagnostic imaging of early-stage Alzheimer's disease

Viola, K. L., Sbarboro, J., Sureka, R., De, M., Bicca, M. A., Wang, J., Vasavada, S. R., Satpathy, S., Wu, S., Joshi, H. M., et al. (2014) · Nature Nanotechnology · doi:10.1038/nnano.2014.254 · Cited by 192 · see citing works

Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer’s disease immunotherapeutics

Goure, W. F., Krafft, G. A., Jerecic, J., & Hefti, F. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt272 · Cited by 190 · see citing works

Out-of-register β-sheets suggest a pathway to toxic amyloid aggregates

Liu, C., Zhao, M., Jiang, L., Cheng, P.-N., Park, J.-Y., Sawaya, M. R., Pensalfini, A., Gou, D., Berk, A. J., Glabe, C. G., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218792109 · Cited by 186 · see citing works

Memantine Rescues Transient Cognitive Impairment Caused by High-Molecular-Weight A Oligomers But Not the Persistent Impairment Induced by Low-Molecular-Weight Oligomers

Figueiredo, C. P., Clarke, J. R., Ledo, J. H., Ribeiro, F. C., Costa, C., Melo, H. M., Mota-Sales, A. P., Saraiva, L. M., Klein, W. L., Sebollela, A. S., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.0482-13.2013 · Cited by 181 · see citing works

Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers I: Abeta 42 Oligomer Binding to Specific Neuronal Receptors Is Displaced by Drug Candidates That Improve Cognitive Deficits

Izzo, N. J., Staniszewski, A., To, L., Fa, M., Teich, A. F., Saeed, F., Wostein, H., Walko, T., Vaswani, A., Wardius, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111898 · Cited by 180 · see citing works

Environmental Novelty Activates β2-Adrenergic Signaling to Prevent the Impairment of Hippocampal LTP by Aβ Oligomers

Li, S., Jin, M., Zhang, D., Yang, T., Koeglsperger, T., Fu, H., & Selkoe, D. J. (2013) · Neuron · doi:10.1016/j.neuron.2012.12.040 · Cited by 177 · see citing works

Fyn Kinase Modulates Synaptotoxicity, But Not Aberrant Sprouting, in Human Amyloid Precursor Protein Transgenic Mice

Chin, J., Palop, J. J., Yu, G.-Q., Kojima, N., Masliah, E., & Mucke, L. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.0277-04.2004 · Cited by 161 · see citing works

Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease

Lannfelt, L., Möller, C., Basun, H., Osswald, G., Sehlin, D., Satlin, A., Logovinsky, V., & Gellerfors, P. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt246 · Cited by 152 · see citing works

Novel Mechanistic Insight into the Molecular Basis of Amyloid Polymorphism and Secondary Nucleation during Amyloid Formation

Jeong, J. S., Ansaloni, A., Mezzenga, R., Lashuel, H. A., & Dietler, G. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.02.005 · Cited by 152 · see citing works

Spreading of amyloid-β peptides via neuritic cell-to-cell transfer is dependent on insufficient cellular clearance

Domert, J., Rao, S. B., Agholme, L., Brorsson, A., Marcusson, J. O., Hallbeck, M., & Nath, S. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.12.019 · Cited by 151 · see citing works

6-Shogaol, an active constituent of ginger, attenuates neuroinflammation and cognitive deficits in animal models of dementia

Moon, M., Kim, H. G., Choi, J. G., Oh, H., Lee, P. K. J., Ha, S. K., Kim, S. Y., Park, Y., Huh, Y., & Oh, M. S. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.04.121 · Cited by 150 · see citing works

Intracellular Aβ-oligomers and early inflammation in a model of Alzheimer's disease

Ferretti, M. T., Bruno, M. A., Ducatenzeiler, A., Klein, W. L., & Cuello, A. C. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.01.007 · Cited by 146 · see citing works

Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease

Hölttä, M., Hansson, O., Andréasson, U., Hertze, J., Minthon, L., Nägga, K., Andreasen, N., Zetterberg, H., & Blennow, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066381 · Cited by 142 · see citing works

Synaptotoxic Amyloid-β Oligomers: A Molecular Basis for the Cause, Diagnosis, and Treatment of Alzheimer's Disease?

Klein, W. L. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-129039 · Cited by 141 · see citing works

Quantitative analysis of the time course of Aβ oligomerization and subsequent growth steps using tetramethylrhodamine-labeled Aβ

Garai, K., & Frieden, C. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222478110 · Cited by 138 · see citing works

Amyloid-β Annular Protofibrils Evade Fibrillar Fate in Alzheimer Disease Brain

Lasagna‐Reeves, C. A., Glabe, C. G., & Kayed, R. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.236257 · Cited by 136 · see citing works

Why Alzheimer trials fail: removing soluble oligomeric beta amyloid is essential, inconsistent, and difficult

Rosenblum, W. I. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.10.085 · Cited by 135 · see citing works

Alzheimer's-associated Aβ oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal

Pitt, J., Roth, W., Lacor, P., Smith, A. B., Blankenship, M., Velasco, P., De Felice, F., Breslin, P., & Klein, W. L. (2009) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.07.018 · Cited by 134 · see citing works

Mechanisms for the Insertion of Toxic, Fibril-like β-Amyloid Oligomers into the Membrane

Jang, H., Connelly, L. S., Arce, F. T., Ramachandran, S., Kagan, B. L., Lal, R., & Nussinov, R. (2012) · Journal of Chemical Theory and Computation · doi:10.1021/ct300916f · Cited by 133 · see citing works

Non-Fibrillar β-Amyloid Protein is Associated with Smooth Muscle Cells of Vessel Walls in Alzheimer Disease

Frackowiak, J., Żółtowska, A., & Wı́sniewski, H. M. (1994) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199411000-00011 · Cited by 128 · see citing works

Intracellular processing of disease-associated α-synuclein in the human brain suggests prion-like cell-to-cell spread

Kovács, G. G., Breydo, L., Green, R. J., Kis, V., Puska, G., Lőrincz, P., Perju‐Dumbrava, L., Giera, R., Pirker, W., Lutz, M. I., et al. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.05.020 · Cited by 128 · see citing works

Donepezil inhibits the amyloid-beta oligomer-induced microglial activation in vitro and in vivo

Kim, H. G., Moon, M., Choi, J. G., Park, G., Kim, A., Hur, J., Lee, K., & Oh, M. S. (2013) · NeuroToxicology · doi:10.1016/j.neuro.2013.10.004 · Cited by 127 · see citing works

Alzheimer’s β-peptide oligomer formation at physiologic concentrations

LeVine, H. (2004) · Analytical Biochemistry · doi:10.1016/j.ab.2004.08.014 · Cited by 123 · see citing works

Metabotropic glutamate receptors transduce signals for neurite outgrowth after binding of the prion protein to laminili γ1 chain

Heraldo, F. H., Arantes, C., Santos, T. G., Machado, C. F., Roffé, M., Haji, G. N., Lee, K. S., Magalhães, A. C., Caetano, F. A., Mancini, G. L., et al. (2010) · The FASEB Journal · doi:10.1096/fj.10-161653 · Cited by 123 · see citing works

The case for soluble Aβ oligomers as a drug target in Alzheimer's disease

Hefti, F. F., Goure, W. F., Jerecı̀ć, J., Iverson, K. S., Walicke, P. A., & Krafft, G. A. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.03.002 · Cited by 119 · see citing works

Purification and Characterization of Brain Clusterin

Oda, T., Pasinetti, G. M., Osterburg, H. H., Anderson, C., Johnson, S. A., & Finch, C. E. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.2580 · Cited by 118 · see citing works

Amyloid-β induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease

Um, J. W., & Strittmatter, S. M. (2013) · Prion · doi:10.4161/pri.22212 · Cited by 113 · see citing works

Architecture of the Alzheimer?s A�P Ion Channel Pore

Arispe, N. J. (2004) · The Journal of Membrane Biology · doi:10.1007/s00232-003-0638-7 · Cited by 111 · see citing works

Atomic force microscopy to study molecular mechanisms of amyloid fibril formation and toxicity in Alzheimer’s disease

Drolle, E., Hane, F. T., Lee, B. Y., & Leonenko, Z. (2014) · Drug Metabolism Reviews · doi:10.3109/03602532.2014.882354 · Cited by 109 · see citing works

The Alzheimer's Amyloid-β(1–42) Peptide Forms Off-Pathway Oligomers and Fibrils That Are Distinguished Structurally by Intermolecular Organization

Tay, W. M., Huang, D., Rosenberry, T. L., & Paravastu, A. K. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.04.003 · Cited by 109 · see citing works

In Vitro and Mechanistic Studies of an Antiamyloidogenic Self-Assembled Cyclic d , l -α-Peptide Architecture

Richman, M., Wilk, S., Chemerovski‐Glikman, M., Wärmländer, S. K. T. S., Wahlström, A., Gräslund, A., & Rahimipour, S. (2013) · Journal of the American Chemical Society · doi:10.1021/ja310064v · Cited by 108 · see citing works

Specific Uptake of an Amyloid-β Protofibril-Binding Antibody-Tracer in AβPP Transgenic Mouse Brain

Magnusson, K., Sehlin, D., Syvänen, S., Svedberg, M. M., Philipson, O., Söderberg, L., Tegerstedt, K., Holmquist, M., Gellerfors, P., Максимилианович, Т. В., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130029 · Cited by 105 · see citing works

Tau-Based Therapeutic Approaches for Alzheimer's Disease - A Mini-Review

Boutajangout, A., & Wısnıewskı, T. (2014) · Gerontology · doi:10.1159/000358875 · Cited by 105 · see citing works

Rare Individual Amyloid-β Oligomers Act on Astrocytes to Initiate Neuronal Damage

Narayan, P. S., Holmström, K. M., Kim, D.-H., Whitcomb, D. J., Wilson, M. R., George‐Hyslop, P. S., Wood, N. W., Dobson, C. M., Cho, K., Abramov, A. Y., et al. (2014) · Biochemistry · doi:10.1021/bi401606f · Cited by 104 · see citing works

Impact of Apolipoprotein E on Alzheimer’s Disease

Hauser, P. S., & Ryan, R. O. (2013) · Current Alzheimer Research · doi:10.2174/15672050113109990156 · Cited by 101 · see citing works

Alzheimer’s disease Aβ assemblies mediating rapid disruption of synaptic plasticity and memory

Klyubin, I. V., Cullen, W. K., Hu, N., & Rowan, M. J. (2012) · Molecular Brain · doi:10.1186/1756-6606-5-25 · Cited by 101 · see citing works

The cellular prion protein traps Alzheimer's Aβ in an oligomeric form and disassembles amyloid fibers

Younan, N. D., Sarell, C. J., Davies, P., Brown, D. R., & Viles, J. H. (2013) · The FASEB Journal · doi:10.1096/fj.12-222588 · Cited by 100 · see citing works

Immunotherapy for Alzheimer's disease

Wısnıewskı, T., & Goñi, F. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.020 · Cited by 99 · see citing works

α-Secretase-derived Fragment of Cellular Prion, N1, Protects against Monomeric and Oligomeric Amyloid β (Aβ)-associated Cell Death

Guillot‐Sestier, M., Sunyach, C., Ferreira, S. T., Marzolo, M., Bauer, C., Thevenet, A., & Checler, F. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.323626 · Cited by 95 · see citing works

Significant Structural Differences between Transient Amyloid‐β Oligomers and Less‐Toxic Fibrils in Regions Known To Harbor Familial Alzheimer′s Mutations

Sarkar, B., Mithu, V. S., Chandra, B., Mandal, A., Chandrakesan, M., Bhowmik, D., Madhu, P. K., & Maiti, S. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201402636 · Cited by 93 · see citing works

Early intervention with a small molecule inhibitor for tumor nefosis factor-α prevents cognitive deficits in a triple transgenic mouse model of Alzheimer’s disease

Gabbita, S. P., Srivastava, M. K., Eslami, P., Johnson, M. F., Kobritz, N., Tweedie, D., Greig, N. H., Zemlan, F. P., Sharma, S. P., & Harris‐White, M. E. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-99 · Cited by 93 · see citing works

Intrahippocampal Administration of Amyloid-β1-42 Oligomers Acutely Impairs Spatial Working Memory, Insulin Signaling, and Hippocampal Metabolism

Pearson-Leary, J., & McNay, E. C. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-112192 · Cited by 91 · see citing works

Mechanism of cholesterol‐assisted oligomeric channel formation by a short Alzheimer β‐amyloid peptide

Scala, C. D., Troadec, J., Lelièvre, C., Garmy, N., Fantini, J., & Chahinian, H. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12390 · Cited by 91 · see citing works

Bapineuzumab

Kerchner, G. A., & Boxer, A. L. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.493872 · Cited by 90 · see citing works

Blocking the Interaction between Apolipoprotein E and Aβ Reduces Intraneuronal Accumulation of Aβ and Inhibits Synaptic Degeneration

Kuszczyk, M. A., Sanchez, S., Pankiewicz, J., Kim, J., Duszczyk, M., Guridi, M., Asuni, A. A., Sullivan, P. M., Holtzman, D. M., & Sadowski, M. J. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.01.034 · Cited by 89 · cited 1× · see citing works

Multivariate Analyses of Amyloid-Beta Oligomer Populations Indicate a Connection between Pore Formation and Cytotoxicity

Prangkio, P., Yusko, E. C., Sept, D., Yang, J., & Mayer, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047261 · Cited by 86 · see citing works

Cognitive and Functional Decline and Their Relationship in Patients with Mild Alzheimer's Dementia

Liu‐Seifert, H., Siemers, E., Sundell, K. L., Price, K., Han, B., Selzler, K. J., Aisen, P. S. S., Cummings, J. L., Raskin, J., & Mohs, R. C. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140792 · Cited by 82 · see citing works

Single Molecule Characterization of the Interactions between Amyloid-β Peptides and the Membranes of Hippocampal Cells

Narayan, P. S., Ganzinger, K. A., McColl, J. T., Weimann, L., Meehan, S., Qamar, S., Carver, J. A., Wilson, M. R., George‐Hyslop, P. S., Dobson, C. M., et al. (2013) · Journal of the American Chemical Society · doi:10.1021/ja3103567 · Cited by 82 · see citing works

C-Terminal Turn Stability Determines Assembly Differences between Aβ40 and Aβ42

Roychaudhuri, R., Yang, M., Deshpande, A. M., Cole, G. M., Frautschy, S. A., Lomakin, A., Benedek, G. B., & Teplow, D. B. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2012.11.006 · Cited by 82 · see citing works

Femtomole Immunodetection of Synthetic and Endogenous Amyloid-β Oligomers and Its Application to Alzheimer's Disease Drug Candidate Screening

Chang, L., Bakhos, L., Wang, Z., Venton, D. L., & Klein, W. L. (2003) · Journal of Molecular Neuroscience · doi:10.1385/jmn:20:3:305 · Cited by 79 · see citing works

Hypercholesterolemia accelerates intraneuronal accumulation of Aβ oligomers resulting in memory impairment in Alzheimer's disease model mice

Umeda, T., Tomiyama, T., Kitajima, E., Idomoto, T., Nomura, S., Lambert, M. P., Klein, W. L., & Mori, H. (2012) · Life Sciences · doi:10.1016/j.lfs.2011.12.022 · Cited by 78 · see citing works

Amyloid-β and Tau Pathology of Alzheimer's Disease Induced by Diabetes in a Rabbit Animal Model

Bitel, C. L., Kasinathan, C., Kaswala, R. H., Klein, W. L., & Frederikse, P. H. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120571 · Cited by 77 · see citing works

Intracellular Accumulation of Toxic Turn Amyloid-β is Associated with Endoplasmic Reticulum Stress in Alzheimer's Disease

Soejima, N., Ohyagi, Y., Nakamura, N., Himeno, E., Iinuma, K., Sakae, N., Yamasaki, R., Tabira, T., Murakami, K., Irie, K., et al. (2013) · Current Alzheimer Research · doi:10.2174/156720513804871372 · Cited by 76 · see citing works

Systemic vaccination with anti‐oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg‐AD mice

Rasool, S., Martínez‐Coria, H., Wu, J., LaFerla, F. M., & Glabe, C. G. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12305 · Cited by 74 · see citing works

Chronic Intranasal Treatment with an Anti-Aβ30-42 scFv Antibody Ameliorates Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease

Cattepoel, S., Hanenberg, M., Kulic, L., & Nitsch, R. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018296 · Cited by 73 · see citing works

Structural Insights into Aβ42 Oligomers Using Site-directed Spin Labeling

Gu, L., Liu, C., & Guo, Z. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.457739 · Cited by 73 · see citing works

Do Astrocytes Collaborate with Neurons in Spreading the “Infectious” Aβ and Tau Drivers of Alzheimer’s Disease?

Prà, I. D., Chiarini, A., Gui, L., Chakravarthy, B., Pacchiana, R., Gardenal, E., Whitfield, J. F., & Armato, U. (2014) · The Neuroscientist · doi:10.1177/1073858414529828 · Cited by 73 · see citing works

Brain interstitial oligomeric amyloid β increases with age and is resistant to clearance from brain in a mouse model of Alzheimer's disease

Takeda, S., Hashimoto, T., Roe, A. D., Hori, Y., Spires‐Jones, T. L., & Hyman, B. T. (2013) · The FASEB Journal · doi:10.1096/fj.13-229666 · Cited by 72 · see citing works

Perispinal etanercept: Potential as an Alzheimer therapeutic

Griffin, W. S. T. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-3 · Cited by 66 · see citing works

Immunotherapy for Alzheimer’s disease

Wilkinson, D. (2005) · CRC Press eBooks · doi:10.1201/b13935-7 · Cited by 65 · see citing works

Amyloid: Little proteins, big clues

Schnabel, J. (2011) · Nature · doi:10.1038/475s12a · Cited by 62 · see citing works

Conformation‐dependent single‐chain variable fragment antibodies specifically recognize beta‐amyloid oligomers

Wang, X.-P., Zhang, J.-H., Wang, Y.-J., Feng, Y. N., Zhang, X., Sun, X.-X., Li, J.-L., Du, X.-T., Lambert, M. P., Yang, S.-G., et al. (2009) · FEBS Letters · doi:10.1016/j.febslet.2008.12.064 · Cited by 61 · see citing works

Correlation of Specific Amyloid-β Oligomers With Tau in Cerebrospinal Fluid From Cognitively Normal Older Adults

Handoko, M., Grant, M. K. O., Kuskowski, M. A., Zahs, K. R., Wallin, A., Blennow, K., & Ashe, K. H. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.48 · Cited by 61 · see citing works

Human Prefoldin Inhibits Amyloid-β (Aβ) Fibrillation and Contributes to Formation of Nontoxic Aβ Aggregates

Sörgjerd, K. M., Zako, T., Sakono, M., Stirling, P. C., Leroux, M. R., Saito, T., Nilsson, P., Sekimoto, M., Saido, T. C., & Maeda, M. (2013) · Biochemistry · doi:10.1021/bi301705c · Cited by 60 · see citing works

Different effects of Alzheimer's peptide Aβ(1–40) oligomers and fibrils on supported lipid membranes

Canale, C., Seghezza, S., Vilasi, S., Carrotta, R., Bulone, D., Diaspro, A., Biagio, P. L. S., & Dante, S. (2013) · Biophysical Chemistry · doi:10.1016/j.bpc.2013.07.010 · Cited by 60 · see citing works

Accumulation of Intraneuronal β-Amyloid 42 Peptides Is Associated with Early Changes in Microtubule-Associated Protein 2 in Neurites and Synapses

Takahashi, R. H., Capetillo‐Zarate, E., Lin, M. T. S., Milner, T. A., & Gouras, G. K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0051965 · Cited by 60 · see citing works

Membrane-Mediated Neuroprotection by Curcumin from Amyloid-β-Peptide-Induced Toxicity

Thapa, A., Vernon, B. C., la Peña, K. D., Soliz, G., Moreno, H. A., López, G. P., & Chi, E. Y. (2013) · Langmuir · doi:10.1021/la4020459 · Cited by 60 · see citing works

Lipid Rafts Mediate Amyloid-Induced Calcium Dyshomeostasis and Oxidative Stress in Alzheimer’s Disease

Evangelisti, E., Wright, D., Zampagni, M., Cascella, R., Fiorillo, C., Bagnoli, S., Relini, A., Nichino, D., Scartabelli, T., Nacmias, B., et al. (2013) · Current Alzheimer Research · doi:10.2174/1567205011310020004 · Cited by 59 · see citing works

Brain Transit and Ameliorative Effects of Intranasally Delivered Anti-Amyloid-β Oligomer Antibody in 5XFAD Mice

Xiao, C., Davis, F., Chauhan, B. C., Viola, K. L., Lacor, P. N., Velasco, P. T., Klein, W. L., & Chauhan, N. B. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-122419 · Cited by 59 · see citing works

Early intervention in the 3xTg-AD mice with an amyloid β-antibody fragment ameliorates first hallmarks of Alzheimer disease

Giménez‐Llort, L., Rivera-Hernández, G., Marin‐Argany, M., Sánchez‐Quesada, J. L., & Villegas, S. (2013) · mAbs · doi:10.4161/mabs.25424 · Cited by 57 · see citing works

Poor Physical Performance and Dementia in the Oldest Old

Bullain, S., Corrada, M. M., Shah, B. A., Mozaffar, F. H., Panzenboeck, M. M., & Kawas, C. H. (2012) · JAMA Neurology · doi:10.1001/jamaneurol.2013.583 · Cited by 56 · see citing works

Thermodynamically stable amyloid-β monomers have much lower membrane affinity than the small oligomers

Sarkar, B., Das, A. K., & Maiti, S. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00084 · Cited by 56 · see citing works

Synapse-Binding Subpopulations of Aβ Oligomers Sensitive to Peptide Assembly Blockers and scFv Antibodies

Velasco, P. T., Heffern, M. C., Sebollela, A. S., Popova, I. A., Lacor, P. N., Lee, K. B., Sun, X., Tiano, B. N., Viola, K. L., Eckermann, A. L., et al. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn300122k · Cited by 55 · see citing works

Prefibrillar Tau Oligomers in Mild Cognitive Impairment and Alzheimer's Disease

Mufson, E. J., Ward, S., & Binder, L. I. (2013) · Neurodegenerative Diseases · doi:10.1159/000353687 · Cited by 54 · see citing works

β-Amyloid oligomers in aging and Alzheimer’s disease

Zahs, K. R., & Ashe, K. H. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00028 · Cited by 53 · see citing works

Conformation-specific antibodies to target amyloid β oligomers and their application to immunotherapy for Alzheimer’s disease

Murakami, K. (2014) · Bioscience Biotechnology and Biochemistry · doi:10.1080/09168451.2014.940275 · Cited by 52 · see citing works

Cellular Prion Protein as a Therapeutic Target in Alzheimer's Disease

Laurén, J. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130950 · Cited by 51 · see citing works

Alzheimer's disease: which type of amyloid-preventing drug agents to employ?

Jang, H., Connelly, L. S., Arce, F. T., Ramachandran, S., Lal, R., Kagan, B. L., & Nussinov, R. (2013) · Physical Chemistry Chemical Physics · doi:10.1039/c3cp00017f · Cited by 50 · see citing works

Structure–Activity Relationships of Organofluorine Inhibitors of β‐Amyloid Self‐Assembly

Török, B., Sood, A., Bag, S., Kulkarni, A., Borkin, D., Lawler, E., Dasgupta, S., Landge, S. M., Abid, M. A., Zhou, W., et al. (2012) · ChemMedChem · doi:10.1002/cmdc.201100569 · Cited by 48 · see citing works

The Arctic AβPP mutation leads to Alzheimer’s disease pathology with highly variable topographic deposition of differentially truncated Aβ

Kalimo, H., Lalowski, M. M., Bogdanović, N., Philipson, O., Bird, T. D., Nochlin, D., Schellenberg, G. D., Brundin, R., Olofsson, T., Soliymani, R., et al. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-60 · Cited by 48 · see citing works

Inhibition of amyloid beta-induced synaptotoxicity by a pentapeptide derived from the glycine zipper region of the neurotoxic peptide

Peters, C., Fernández-Pérez, E. J., Burgos, C. F., Flores-Espinoza, M. P., Castillo, C., Urrutia, J. C., Streltsov, V. A., Opazo, C., & Aguayo, L. G. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.06.001 · Cited by 46 · see citing works

Amyloid-β Protein Modulates Insulin Signaling in Presynaptic Terminals

Heras-Sandoval, D., Ferrera, P., & Arias, C. (2012) · Neurochemical Research · doi:10.1007/s11064-012-0800-7 · Cited by 45 · see citing works

Cyclic AMP Enhancers and Aβ Oligomerization Blockers as Potential Therapeutic Agents in Alzheimers Disease

Wasilewska‐Sampaio, A. P., Barbosa, A. C. A. P., Gomes, F. C. A., & Ferreira, S. T. (2007) · Current Alzheimer Research · doi:10.2174/156720507781077287 · Cited by 43 · see citing works

Specific Domains of Aβ Facilitate Aggregation on and Association with Lipid Bilayers

Yates, E. A., Owens, S. L., Lynch, M. F., Cucco, E. M., Umbaugh, C. S., & Legleiter, J. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.03.022 · Cited by 41 · see citing works

Specific Soluble Oligomers of Amyloid-β Peptide Undergo Replication and Form Non-fibrillar Aggregates in Interfacial Environments

Kumar, A., Paslay, L. C., Lyons, D. F., Morgan, S. E., Correia, J. J., & Rangachari, V. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.355156 · Cited by 40 · see citing works

Continuation of Exercise Is Necessary to Inhibit High Fat Diet-Induced β-Amyloid Deposition and Memory Deficit in Amyloid Precursor Protein Transgenic Mice

Maesako, M., Uemura, K., Iwata, A., Kubota, M., Watanabe, K., Uemura, M. T., Noda, Y., Asada‐Utsugi, M., Kihara, T., Takahashi, R., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072796 · Cited by 39 · see citing works

Factors Influencing Compact–Extended Structure Equilibrium in Oligomers of Aβ1–40 Peptide—An Ion Mobility Mass Spectrometry Study

Sitkiewicz, E., Kłoniecki, M., Poznański, J. T., Bal, W., & Dadlez, M. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2014.05.015 · Cited by 38 · see citing works

Immunotherapy alleviates amyloid-associated synaptic pathology in an Alzheimer’s disease mouse model

Dorostkar, M. M., Burgold, S., Filser, S., Barghorn, S., Schmidt, B., Anumala, U. R., Hillen, H., Klein, C., & Herms, J. W. (2014) · Brain · doi:10.1093/brain/awu280 · Cited by 38 · see citing works

Plasma Membrane Injury Depends on Bilayer Lipid Composition in Alzheimer's Disease

Evangelisti, E., Zampagni, M., Cascella, R., Becatti, M., Fiorillo, C., Caselli, A., Bagnoli, S., Nacmias, B., & Cecchi, C. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131406 · Cited by 37 · see citing works

Rosiglitazone Prevents Amyloid-β Oligomer-Induced Impairment of Synapse Formation and Plasticity via Increasing Dendrite and Spine Mitochondrial Number

Xu, S., Guilan, L., Bao, X., Wu, J., Li, S., Zheng, B., Anwyl, R., & Wang, Q. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-130680 · Cited by 35 · see citing works

Nanoscale Synaptic Membrane Mimetic Allows Unbiased High Throughput Screen That Targets Binding Sites for Alzheimer’s-Associated Aβ Oligomers

Wilcox, K. C., Marunde, M. R., Das, A., Velasco, P. T., Kuhns, B. D., Marty, M. T., Haoming, J., Luan, C.-H., Sligar, S. G., & Klein, W. L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125263 · Cited by 34 · see citing works

Kinetic studies of inhibition of the amyloid beta (1–42) aggregation using a ferrocene-tagged β-sheet breaker peptide

Zhang, L., Yagnik, G. B., Peng, Y., Wang, J., Xu, H. H., Hao, Y., Liu, Y., & Zhou, F. (2012) · Analytical Biochemistry · doi:10.1016/j.ab.2012.11.025 · Cited by 34 · see citing works

Toxicity in Rat Primary Neurons through the Cellular Oxidative Stress Induced by the Turn Formation at Positions 22 and 23 of Aβ42

Izuo, N., Kume, T., Sato, M., Murakami, K., Irie, K., Izumi, Y., & Akaike, A. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn300033k · Cited by 34 · see citing works

Structural Diversity of Alzheimer's Disease Amyloid-β Dimers and Their Role in Oligomerization and Fibril Formation

Tsigelny, I. F., Sharikov, Y., Kouznetsova, V. L., Greenberg, J. P., Wrasidlo, W., Gonzalez, T., Desplats, P., Michael, S. E., Trejo, M., Overk, C., et al. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131589 · Cited by 33 · see citing works

Sortilin is required for toxic action of Aβ oligomers (AβOs): Extracellular AβOs trigger apoptosis, and intraneuronal AβOs impair degradation pathways

Takamura, A., Sato, Y., Watabe, D., Okamoto, Y., Nakata, T., Kawarabayashi, T., Oddo, S., LaFerla, F. M., Shoji, M., & Matsubara, E. (2012) · Life Sciences · doi:10.1016/j.lfs.2012.04.038 · Cited by 33 · see citing works

Tissue Transglutaminase in Alzheimer's Disease: Involvement in Pathogenesis and its Potential as a Therapeutic Target

Wilhelmus, M. M. M., de Jager, M., Bakker, E. N. T. P., & Drukarch, B. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132492 · Cited by 32 · see citing works

Intracellular Localization of Amyloid-β Peptide in SH-SY5Y Neuroblastoma Cells

Zheng, L. P., Calvo‐Garrido, J., Hallbeck, M., Hultenby, K. R., Marcusson, J. O., Cedazo-Mı́nguez, Á., & Terman, A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-122455 · Cited by 31 · see citing works

Metals, Membranes, and Amyloid-β Oligomers: Key Pieces in the Alzheimer's Disease Puzzle?

Watt, A. D., Villemagne, V. L., & Barnham, K. J. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-129017 · Cited by 31 · see citing works

The Off-rate of Monomers Dissociating from Amyloid-β Protofibrils

Grüning, C. S. R., Klinker, S., Wolff, M., Schneider, M., Toksöz, K., Klein, A. N., Nagel‐Steger, L., Willbold, D., & Hoyer, W. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.513432 · Cited by 31 · see citing works

Effect of α-Synuclein on Amyloid β-Induced Toxicity: Relevance to Lewy Body Variant of Alzheimer Disease

Resende, R., Marques, S., Ferreiro, E. B., Simões, I., Oliveira, C. R., & Pereira, C. (2013) · Neurochemical Research · doi:10.1007/s11064-013-0982-7 · Cited by 31 · see citing works

Structural evolution and membrane interactions of Alzheimer's amyloid‐beta peptide oligomers: New knowledge from single‐molecule fluorescence studies

Johnson, R. D., Steel, D. G., & Gafni, A. (2014) · Protein Science · doi:10.1002/pro.2479 · Cited by 29 · see citing works

Amyloid β peptides modify the expression of antioxidant repair enzymes and a potassium channel in the septohippocampal system

Durán-González, J., Michi, E. D., Elorza, B., Perez-Cordova, M. G., Otalora, L. F. P., Touhami, A., Paulson, P. E., Perry, G. L., Murray, I. V. J., & Colom, L. V. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.02.005 · Cited by 28 · see citing works

Pan-Amyloid Oligomer Specific scFv Antibody Attenuates Memory Deficits and Brain Amyloid Burden in Mice with Alzheimer’s Disease

Zhao, M., Wang, S., Wang, Y., Zhang, R., Li, Y., Su, Y.-J., Zhou, W.-W., Yu, X., & Liu, R. (2014) · Current Alzheimer Research · doi:10.2174/15672050113106660176 · Cited by 28 · see citing works

Gly25-Ser26 amyloid β-protein structural isomorphs produce distinct Aβ42 conformational dynamics and assembly characteristics

Roychaudhuri, R., Lomakin, A., Bernstein, S. L., Zheng, X.-Y., Condron, M., Benedek, G., Bowers, M., & Teplow, D. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2014.04.004 · Cited by 27 · see citing works

Plasma Amyloid-β Oligomers and Soluble Tumor Necrosis Factor Receptors as Potential Biomarkers of AD

Zhang, J., Mao, P., & Jia, J. (2014) · Current Alzheimer Research · doi:10.2174/1567205011666140317103222 · Cited by 27 · see citing works

Selective inhibition of the membrane attack complex of complement by low molecular weight components of the aurin tricarboxylic acid synthetic complex

Lee, M., Guo, J., Schwab, C., McGeer, E. G., & McGeer, P. L. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.12.005 · Cited by 27 · see citing works

Immunogenic properties of amyloid beta oligomers

Dalgediene, I., Lasickiene, R., Budvytyte, R., Valincius, G., Morkuniene, R., Borutaite, V., & Zvirbliene, A. (2013) · Journal of Biomedical Science · doi:10.1186/1423-0127-20-10 · Cited by 22 · see citing works

Antibodies bound to Aβ oligomers potentiate the neurotoxicity of Aβ by activating microglia

Morkūnienė, R., Žvirblienė, A., Dalgėdienė, I., Čižas, P., Jankevičiūtė, S., Baliūtytė, G., Jokubka, R., Jankunec, M., Valinčius, G., & Borutaitė, V. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12332 · Cited by 21 · see citing works

Changes in insulin-signaling transduction pathway underlie learning/memory deficits in an Alzheimer’s disease rat model

Han, X., Ma, Y., Liu, X., Wang, L., Qi, S., Zhang, Q., & Du, Y. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-012-0803-1 · Cited by 20 · see citing works

Expression Profile of Rat Hippocampal Neurons Treated with the Neuroprotective Compound 2,4-Dinitrophenol: Up-Regulation of cAMP Signaling Genes

Sebollela, A., Freitas-Corrêa, L., de Oliveira, F. F., Mendes, C. T., Wasilewska‐Sampaio, A. P., Camacho-Pereira, J., Galina, A., Brentani, H., Passetti, F., Felice, F. G. D., et al. (2009) · Neurotoxicity Research · doi:10.1007/s12640-009-9133-y · Cited by 20 · see citing works

Different effects of soluble and aggregated amyloid β42 on gene/protein expression and enzyme activity involved in insulin and APP pathways

Bartl, J., Meyer, A. H., Brendler, S., Riederer, P., & Grünblatt, E. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-012-0852-5 · Cited by 19 · see citing works

Anti-Amyloid-β-Mediated Positron Emission Tomography Imaging in Alzheimer's Disease Mouse Brains

McLean, D., Cooke, M. J., Wang, Y., Green, D., Fraser, P. E., George‐Hyslop, P. S., & Shoichet, M. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051958 · Cited by 14 · see citing works

Aminostyrylbenzofuran Directly Reduces Oligomeric Amyloid-β and Reverses Cognitive Deficits in Alzheimer Transgenic Mice

Lee, S.-H., Kim, Y. S., Kim, H. Y., Kim, Y. H., Kim, M. S., Kong, J. Y., Lee, M.-H., Kim, D. J., & Ahn, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095733 · Cited by 13 · see citing works

Disease Modifying Therapies for Alzheimer's Disease Targeting AβOligomers: Implications for Therapeutic Mechanisms

Matsubara, E., Takamura, A., Okamoto, Y., Oono, H., Nakata, T., Wakasaya, Y., Kawarabayashi, T., & Shoji, M. (2013) · BioMed Research International · doi:10.1155/2013/984041 · Cited by 12 · see citing works

In Vivo and Ex Vivo Imaging of Amyloid-β Cascade Aggregates with a Pronucleon™ Peptide

Nyborg, A. C., Moll, J. R., Wegrzyn, R. D., Havas, D., Hutter‐Paier, B., Feurstein, G., & Rudolph, A. S. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-122107 · Cited by 11 · see citing works

Apolipoprotein E receptor pathways in Alzheimer disease

Schmidt, V., Carlo, A.-S., & Willnow, T. E. (2014) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1262 · Cited by 10 · see citing works

Conformation-Dependent Oligomers in Cerebrospinal Fluid of Presymptomatic Familial Alzheimer’s Disease Mutation Carriers

Ringman, J. M., Tomic, J. L., Coppola, G., Elashoff, D. A., Gylys, K. H., & Glabe, C. G. (2012) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000345771 · Cited by 9 · see citing works

Construction of human Fab library and screening of a single-domain antibody of amyloid-beta 42 oligomers.

Yuan, Z., Du, M., Chen, Y., & Dou, F. (2013) · PubMed Central · doi:10.3969/j.issn.1673-5374.2013.33.004 · Cited by 6 · see citing works

NEWS FROM THE SOCIETY FOR NEUROSCIENCE ANNUAL MEETING

Robinson, R. J. (2012) · Neurology Today · doi:10.1097/01.nt.0000425719.88852.88 · Cited by 2 · see citing works

Untitled work

Barbero (2014) · doi:10.1016/j · Cited by 1 · see citing works

Single-strand annealing between inverted DNA repeats: Pathway choice, participating proteins, and genome destabilizing consequences

(2018) · Digital Commons@Becker (Washington University School of Medicine) · doi:10.1371/journal

The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade

Cline, E. N., Bicca, M. A., Viola, K. L., & Klein, W. L. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179941 · Cited by 870 · see citing works

Alzheimer's disease: experimental models and reality

Drummond, E., & Wisniewski, T. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1662-x · Cited by 810 · see citing works

A vicious cycle of β amyloid−dependent neuronal hyperactivation

Zott, B., Simon, M. M., Hong, W., Unger, F., Chen-Engerer, H.-J., Frosch, M. P., Sakmann, B., Walsh, D. M., & Konnerth, A. (2019) · Science · doi:10.1126/science.aay0198 · Cited by 640 · see citing works

Alzheimer's Disease: Treatment Strategies and Their Limitations.

Passeri, E., Elkhoury, K., Morsink, M., Broersen, K., Linder, M., Tamayol, A., Malaplate, C., Yen, F. T., & Arab-Tehrany, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213954 · Cited by 592 · see citing works

Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease

Söderberg, L., Johannesson, M., Nygren, P., Laudon, H., Eriksson, F., Osswald, G., Möller, C., & Lannfelt, L. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01308-6 · Cited by 444 · see citing works

The amyloid cascade hypothesis: are we poised for success or failure?

Karran, E., & De Strooper, B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13632 · Cited by 402 · see citing works

Soluble amyloid-β oligomers as synaptotoxins leading to cognitive impairment in Alzheimer’s disease

Ferreira, S. T., Lourenco, M. V., Oliveira, M. M., & De Felice, F. G. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00191 · Cited by 373 · see citing works

Amyloid Beta in Aging and Alzheimer’s Disease

Sehar, U., Rawat, P., Reddy, A. P., Kopel, J. J., & Reddy, P. H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112924 · Cited by 385 · see citing works

Aducanumab, gantenerumab, BAN2401, and ALZ-801—The first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval

Tolar, M., Abushakra, S., Hey, J. A., Porsteinsson, A., & Sabbagh, M. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00663-w · Cited by 354 · see citing works

Alzheimer's disease: From immunotherapy to immunoprevention

Jucker, M., & Walker, L. C. (2023) · Cell · doi:10.1016/j.cell.2023.08.021 · Cited by 353 · see citing works

Insulin Resistance and Neurodegeneration: Progress towards the Development of New Therapeutics for Alzheimer's Disease

de la Monte, S. M. (2017) · Drugs · doi:10.1007/s40265-016-0674-0 · Cited by 331 · see citing works

The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease

the Synaptic Health Endpoints Working Group, Colom-Cadena, M., Spires-Jones, T., Zetterberg, H., Blennow, K., Caggiano, A., DeKosky, S. T., Fillit, H., Harrison, J. E., Schneider, L. S., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00588-4 · Cited by 328 · see citing works

Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer’s disease: a systematic review

Jeremic, D., Jiménez-Díaz, L., & Navarro-López, J. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101496 · Cited by 306 · see citing works

Role of tau protein in Alzheimer’s disease: The prime pathological player

Muralidar, S., Ambi, S. V., Sekaran, S., Thirumalai, D., & Palaniappan, B. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.07.327 · Cited by 278 · see citing works

Clearance of cerebral Aβ in Alzheimer’s disease: reassessing the role of microglia and monocytes

Zuroff, L. R., Daley, D. A., Black, K. L., & Koronyo‐Hamaoui, M. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2463-7 · Cited by 275 · see citing works

Amyloid-β Receptors: The Good, the Bad, and the Prion Protein

Jarosz-Griffiths, H. H., Noble, E., Rushworth, J. V., & Hooper, N. M. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.702704 · Cited by 256 · see citing works

Memantine for the Treatment of Dementia: A Review on its Current and Future Applications

Folch, J., Busquets, O., Ettcheto, M., Sánchez-López, E., Castro-Torres, R. D., Verdaguer, E., Garcia, M. L., Olloquequi, J., Casadesús, G., Beas-Zarate, C., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170672 · Cited by 245 · see citing works

Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer’s Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression

Tolar, M., Hey, J., Power, A., & Abushakra, S. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126355 · Cited by 246 · see citing works

Zebrafish: an emerging real-time model system to study Alzheimer’s disease and neurospecific drug discovery

Saleem, S., & Kannan, R. R. (2018) · Cell Death Discovery · doi:10.1038/s41420-018-0109-7 · Cited by 241 · see citing works

Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer’s disease

Sehlin, D., Fang, X. T., Cato, L., Antoni, G., Lannfelt, L., & Syvänen, S. (2016) · Nature Communications · doi:10.1038/ncomms10759 · Cited by 223 · see citing works

The Ambiguous Relationship of Oxidative Stress, Tau Hyperphosphorylation, and Autophagy Dysfunction in Alzheimer’s Disease

Liu, Z., Li, T., Li, P., Wei, N., Zhao, Z., Liang, H., Ji, X., Chen, W., Xue, M., & Wei, J. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/352723 · Cited by 208 · see citing works

Challenges for Alzheimer's Disease Therapy: Insights from Novel Mechanisms Beyond Memory Defects

Frozza, R. L., Lourenco, M. V., & Felice, F. G. D. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00037 · Cited by 202 · see citing works

Diffusible, highly bioactive oligomers represent a critical minority of soluble Aβ in Alzheimer’s disease brain

Hong, W., Wang, Z., Liu, W., O’Malley, T. T., Jin, M., Willem, M., Haass, C., Frosch, M. P., & Walsh, D. M. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1846-7 · Cited by 166 · see citing works

The Role of ADAM10 in Alzheimer’s Disease

Yuan, X., Sun, S., Tan, C., Yu, J., & Tan, L. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170061 · Cited by 160 · see citing works

Imbalanced cholesterol metabolism in Alzheimer's disease

Xue-shan, Z., Peng, J., Wu, Q., Zhong, R., Li-hong, P., Tang, Z., Jiang, Z., Wang, G., & Liu, L. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.02.024 · Cited by 155 · see citing works

Amyloid β oligomers (AβOs) in Alzheimer’s disease

Mroczko, B., Groblewska, M., Litman‐Zawadzka, A., Kornhuber, J., & Lewczuk, P. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1820-x · Cited by 146 · see citing works

The Role of the JAK/STAT Signaling Pathway in the Pathogenesis of Alzheimer’s Disease: New Potential Treatment Target

Rusek, M., Smith, J., El-Khatib, K., Aikins, K., Czuczwar, S. J., & Pluta, R. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24010864 · Cited by 145 · see citing works

The National Institute on Aging—Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trials

Cummings, J. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.05.006 · Cited by 140 · see citing works

Revisiting thioflavin T (ThT) fluorescence as a marker of protein fibrillation – The prominent role of electrostatic interactions

Arad, E., Green, H., Jelinek, R., & Rapaport, H. (2020) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2020.03.075 · Cited by 140 · see citing works

Galectin-3 promotes Aβ oligomerization and Aβ toxicity in a mouse model of Alzheimer’s disease

Tao, C.-C., Cheng, K.-M., Ma, Y.-L., Hsu, W.-L., Chen, Y.-C., Fuh, J.-L., Lee, W.-J., Chao, C.-C., & Lee, E. H. Y. (2020) · Cell Death & Differentiation · doi:10.1038/s41418-019-0348-z · Cited by 138 · see citing works

Biomimetic Dendrimer–Peptide Conjugates for Early Multi‐Target Therapy of Alzheimer's Disease by Inflammatory Microenvironment Modulation

Liu, P., Zhang, T., Chen, Q., Li, C., Chu, Y., Guo, Q., Zhang, Y., Zhou, W., Chen, H., Zhou, Z., et al. (2021) · Advanced Materials · doi:10.1002/adma.202100746 · Cited by 137 · see citing works

Aβ and tau prion-like activities decline with longevity in the Alzheimer’s disease human brain

Aoyagi, A., Condello, C., Stöhr, J., Yue, W., Rivera, B. M., Lee, J. C., Woerman, A. L., Halliday, G. M., van Duinen, S. G., Ingelsson, M., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aat8462 · Cited by 130 · see citing works

APOE-amyloid interaction: Therapeutic targets

Wısnıewskı, T., & Drummond, E. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104784 · Cited by 125 · see citing works

Alzheimer's disease failed clinical trials

Asher, S., & Priefer, R. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120861 · Cited by 124 · see citing works

Brain metabolic stress and neuroinflammation at the basis of cognitive impairment in Alzheimer’s disease

Felice, F. G. D., & Lourenco, M. V. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00094 · Cited by 120 · see citing works

Counteracting the effects of TNF receptor‐1 has therapeutic potential in Alzheimer's disease

Steeland, S., Gorlé, N., Vandendriessche, C., Balusu, S., Brkić, M., Cauwenberghe, C. V., Imschoot, G. V., Wonterghem, E. V., Rycke, R. M. D., Kremer, A., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708300 · Cited by 119 · see citing works

Chiral modulation of amyloid beta fibrillation and cytotoxicity by enantiomeric carbon dots

Malishev, R., Arad, E., Bhunia, S. K., Shaham‐Niv, S., Kolusheva, S., Gazit, E., & Jelinek, R. (2018) · Chemical Communications · doi:10.1039/c8cc03235a · Cited by 122 · see citing works

Exploring ER stress response in cellular aging and neuroinflammation in Alzheimer's disease

Uddin, M. S., Yu, W. S., & Lim, L. W. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101417 · Cited by 118 · see citing works

Oligomeropathies and pathogenesis of Alzheimer and Parkinson's diseases

Forloni, G., Artuso, V., Vitola, P. L., & Balducci, C. (2016) · Movement Disorders · doi:10.1002/mds.26624 · Cited by 115 · see citing works

Biomimetic ApoE-Reconstituted High Density Lipoprotein Nanocarrier for Blood–Brain Barrier Penetration and Amyloid Beta-Targeting Drug Delivery

Song, Q., Song, H., Xu, J., Huang, J., Meng, H., Gu, X. Q., Chen, J., Zheng, G., Chen, H., & Gao, X. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00781 · Cited by 113 · see citing works

A phase 1 clinical trial of the sigma‐2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease

Grundman, M., Morgan, R. E., Lickliter, J. D., Schneider, L. S., DeKosky, S. T., Izzo, N. J., Guttendorf, R. J., Higgin, M., Pribyl, J., Mozzoni, K., et al. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.11.001 · Cited by 110 · see citing works

Elucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer’s Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data

Kočiš, P., Tolar, M., Yu, Y., Sinko, W., Ray, S. S., Blennow, K., Fillit, H. M., & Hey, J. A. (2017) · CNS Drugs · doi:10.1007/s40263-017-0434-z · Cited by 110 · see citing works

Native Ion Mobility-Mass Spectrometry Reveals the Formation of β-Barrel Shaped Amyloid-β Hexamers in a Membrane-Mimicking Environment

Österlund, N., Moons, R., Ilag, L. L., Sobott, F., & Gräslund, A. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b04596 · Cited by 110 · see citing works

Detectable Neuropsychological Differences in Early Preclinical Alzheimer’s Disease: A Meta-Analysis

Han, D.-K. S., Nguyen, C. P., Stricker, N., & Nation, D. (2017) · Neuropsychology Review · doi:10.1007/s11065-017-9345-5 · Cited by 103 · see citing works

Alzheimer’s Disease: Etiology, Neuropathology and Pathogenesis

Sheppard, O., & Coleman, M. P. (2020) · Exon Publications eBooks · doi:10.36255/exonpublications.alzheimersdisease.2020.ch1 · Cited by 112 · see citing works

Linking the Amyloid, Tau, and Mitochondrial Hypotheses of Alzheimer’s Disease and Identifying Promising Drug Targets

Fišar, Z. (2022) · Biomolecules · doi:10.3390/biom12111676 · Cited by 110 · see citing works

Phosphorylation of the amyloid β-peptide at Ser26 stabilizes oligomeric assembly and increases neurotoxicity

Kumar, S., Wirths, O., Stüber, K., Wunderlich, P., Koch, P., Theil, S., Rezaei‐Ghaleh, N., Zweckstetter, M., Bayer, T. A., Brüstle, O., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1546-0 · Cited by 106 · see citing works

Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification

Izzo, N. J., Yuede, C. M., Mozzoni, K., Limegrover, C. S., Rehak, C., Yurko, R., Waybright, L., Look, G. C., Rishton, G. M., Safferstein, H., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12302 · Cited by 101 · see citing works

Hippocampal Injections of Oligomeric Amyloid β-peptide (1–42) Induce Selective Working Memory Deficits and Long-lasting Alterations of ERK Signaling Pathway

Faucher, P., Mons, N., Micheau, J., Louis, C., & Beracochea, D. J. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00245 · Cited by 100 · see citing works

Evaluation of the neuroprotective effect of taurine in Alzheimer’s disease using functional molecular imaging

Oh, S. J., Lee, H., Jeong, Y. J., Nam, K. R., Kang, K. J., Han, S. J., Lee, K. C., Lee, Y. J., & Choi, J. Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-72755-4 · Cited by 100 · see citing works

The role of ubiquitin proteasomal system and autophagy-lysosome pathway in Alzheimer’s disease

Zhang, Y., Chen, X., Zhao, Y., Ponnusamy, M., & Liu, Y. (2017) · Reviews in the Neurosciences · doi:10.1515/revneuro-2017-0013 · Cited by 99 · see citing works

Decoding Neurodegeneration: A Review of Molecular Mechanisms and Therapeutic Advances in Alzheimer’s, Parkinson’s, and ALS

Toader, C., Tătaru, C. P., Munteanu, O., Șerban, M., Covache-Busuioc, R.-A., Ciurea, A. V., & Enyedi, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312613 · Cited by 106 · see citing works

Multi-target-directed phenol–triazole ligands as therapeutic agents for Alzheimer's disease

Jones, M. R., Mathieu, É., Dyrager, C., Faissner, S., Vaillancourt, Z., Korshavn, K. J., Lim, M. H., Ramamoorthy, A., Yong, V. W., Tsutsui, S., et al. (2017) · Chemical Science · doi:10.1039/c7sc01269a · Cited by 96 · see citing works

P‐glycoprotein: a role in the export of amyloid‐β in Alzheimer's disease?

Chai, A. B., Leung, G. K. F., Callaghan, R., & Gelissen, I. C. (2019) · FEBS Journal · doi:10.1111/febs.15148 · Cited by 98 · see citing works

Asperterpenes A and B, two unprecedented meroterpenoids from Aspergillus terreus with BACE1 inhibitory activities

Qi, C., Bao, J., Wang, J., Zhu, H., Xue, Y., Wang, X., Li, H., Sun, W., Gao, W., Lai, Y., et al. (2016) · Chemical Science · doi:10.1039/c6sc02464e · Cited by 95 · see citing works

TREM2 in Alzheimer’s Disease: Microglial Survival and Energy Metabolism

Zheng, H., Cheng, B., Li, Y., Li, X., Chen, X., & Zhang, Y.-W. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00395 · Cited by 94 · see citing works

Melatonin alleviates cognition impairment by antagonizing brain insulin resistance in aged rats fed a high‐fat diet

Xu, J., Gao, H. Y., Zhang, L., Rong, S., Yang, W. Q., Ma, C., Chen, M., Huang, Q., Deng, Q., & Huang, F. (2019) · Journal of Pineal Research · doi:10.1111/jpi.12584 · Cited by 93 · see citing works

Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer’s disease

Tanner, J. A., Iaccarino, L., Edwards, L., Asken, B. M., Gorno‐Tempini, M. L., Kramer, J. H., Pham, J. Q., Perry, D. C., Possin, K. L., Malpetti, M., et al. (2022) · Brain · doi:10.1093/brain/awac229 · Cited by 88 · see citing works

The relationship between amyloid-beta and brain capillary endothelial cells in Alzheimer’s disease

Su, Q., Guo, J.-H., Zhang, Y.-L., Wang, J., & Zhang, Z.-N. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.335829 · Cited by 91 · see citing works

Deuterated polyunsaturated fatty acids reduce brain lipid peroxidation and hippocampal amyloid β-peptide levels, without discernable behavioral effects in an APP/PS1 mutant transgenic mouse model of Alzheimer's disease

Raefsky, S. M., Furman, R., Milne, G., Pollock, E., Axelsen, P., Mattson, M. P., & Shchepinov, M. S. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.02.024 · Cited by 90 · see citing works

Amyloid-β and Tau in Alzheimer’s disease: pathogenesis, mechanisms, and interplay

Abdulkhaliq, A. A., Kim, B., Almoghrabi, Y. M., Khan, J., Ajoolabady, A., Ren, J., Bahijri, S., Tuomilehto, J., Borai, A., & Pratico, D. (2026) · Cell Death & Disease · doi:10.1038/s41419-025-08186-8 · Cited by 87 · see citing works

Near-Infrared Fluorescent Probes as Imaging and Theranostic Modalities for Amyloid-Beta and Tau Aggregates in Alzheimer’s Disease

Rai, H., Gupta, S., Kumar, S., Yang, J., Singh, S. K., Ran, C., & Modi, G. P. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01619 · Cited by 86 · see citing works

Naturally Occurring Antioxidant Therapy in Alzheimer’s Disease

Collins, A. E., Saleh, T. M., & Kalisch, B. E. (2022) · Antioxidants · doi:10.3390/antiox11020213 · Cited by 87 · see citing works

Amyloid β‐induced astrogliosis is mediated by β1‐integrin via NADPH oxidase 2 in Alzheimer's disease

Wyssenbach, A., Quintela‐López, T., Llavero, F., Zugaza, J. L., Matute, C., & Alberdi, E. M. (2016) · Aging Cell · doi:10.1111/acel.12521 · Cited by 81 · see citing works

Sulforaphane Inhibits the Generation of Amyloid- β Oligomer and Promotes Spatial Learning and Memory in Alzheimer’s Disease (PS1V97L) Transgenic Mice

Hou, T., Yang, H., Wang, W., Wu, Q., Tian, Y., & Jia, J. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-171110 · Cited by 84 · see citing works

Alzheimer's Disease Puzzle: Delving into Pathogenesis Hypotheses

(2024) · aging and disease · doi:10.14336/ad.2023.0608 · Cited by 183 · see citing works

Protein Phosphorylation is a Key Mechanism in Alzheimer’s Disease

Oliveira, J., Costa, M., de Almeida, M. S. C., Silva, O. A. B. D. C. E., & Henriques, A. G. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170176 · Cited by 68 · see citing works

Aβ oligomers trigger necroptosis-mediated neurodegeneration via microglia activation in Alzheimer’s disease

Salvadores, N., Moreno‐González, I., Gamez, N., Quiroz, G., Vegas‐Gomez, L., Escandón, M., Jiménez, S., Vitórica, J., Gutiérrez, A., Soto, C. A., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01332-9 · Cited by 81 · see citing works

Therapeutic utility of mesenchymal stromal cell (MSC)-based approaches in chronic neurodegeneration: a glimpse into underlying mechanisms, current status, and prospects

Rahbaran, M., Zekiy, A. O., Bahramali, M., Jahangir, M., Mardasi, M., Sakhaei, D., Thangavelu, L. P., Shomali, N., Zamani, M., Mohammadi, A., et al. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00359-z · Cited by 80 · see citing works

Nanoscale structure of amyloid-β plaques in Alzheimer’s disease

Querol‐Vilaseca, M., Colom‐Cadena, M., Pegueroles, J., Núñez‐Llaves, R., Luque-Cabecerans, J., Muñoz, L., Andilla, J., Belbin, O., Spires‐Jones, T. L., Gelpí, E., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-41443-3 · Cited by 77 · see citing works

Magnolol alleviates Alzheimer's disease-like pathology in transgenic C. elegans by promoting microglia phagocytosis and the degradation of beta-amyloid through activation of PPAR-γ

Xie, Z., Zhao, J., Wang, H., Jiang, Y., Yang, Q., Fu, Y., Zeng, H., Hölscher, C., Xu, J., & Zhang, Z. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.109886 · Cited by 77 · see citing works

Pre-Clinical Neuroprotective Evidences and Plausible Mechanisms of Sulforaphane in Alzheimer’s Disease

Kim, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062929 · Cited by 77 · see citing works

Fluoro-substituted cyanine for reliable in vivo labelling of amyloid-β oligomers and neuroprotection against amyloid-β induced toxicity

Li, Y., Xu, D., Sun, A., Ho, S., Poon, C., Chan, H., Ng, O. T.-W., Yung, K. K. L., Yan, H., Li, H., et al. (2017) · Chemical Science · doi:10.1039/c7sc03974c · Cited by 77 · see citing works

Neuroprotective effects of salidroside through PI3K/Akt pathway activation in Alzheimer’s disease models

Chen, S., Zhang, B., Wang, Y., Li, H., Xiong, R., Zhao, Z., Chu, X., Li, Q., & Sun, S. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s99958 · Cited by 75 · see citing works

Protective effect of melatonin on soluble Aβ1–42-induced memory impairment, astrogliosis, and synaptic dysfunction via the Musashi1/Notch1/Hes1 signaling pathway in the rat hippocampus

Zhang, S., Wang, P., Ren, L., Hu, C., & Bi, J. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0206-x · Cited by 74 · see citing works

Behavioral and neural network abnormalities in human APP transgenic mice resemble those of App knock-in mice and are modulated by familial Alzheimer's disease mutations but not by inhibition of BACE1

Johnson, E. C. B., Ho, K., Yu, G.-Q., Das, M., Sanchez, P. E., Djukic, B., Lopez, I., Yu, X., Gill, M., Zhang, W., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00393-5 · Cited by 73 · see citing works

Posttranslational modification impact on the mechanism by which amyloid‐β induces synaptic dysfunction

Grochowska, K. M., Yuanxiang, P., Bär, J., Raman, R., Brugal, G. N., Sahu, G., Schweizer, M., Bikbaev, A. F., Schilling, S., Demuth, H., et al. (2017) · EMBO Reports · doi:10.15252/embr.201643519 · Cited by 73 · see citing works

Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain

Hey, J. A., Kočiš, P., Hort, J., Abushakra, S. R., Power, A., Vyhnálek, M., Yu, Y., & Tolar, M. (2018) · CNS Drugs · doi:10.1007/s40263-018-0554-0 · Cited by 73 · see citing works

Morin reverses neuropathological and cognitive impairments in APPswe/PS1dE9 mice by targeting multiple pathogenic mechanisms

Du, Y., Qu, J., Zhang, W., Bai, M., Zhou, Q., Zhang, Z., Li, Z., & Miao, J. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.04.008 · Cited by 72 · see citing works

Honokiol Alleviates Cognitive Deficits of Alzheimer’s Disease (PS1 V97L ) Transgenic Mice by Activating Mitochondrial SIRT3

Li, H., Jia, J., Wang, W., Hou, T., Tian, Y., Wu, Q., Xu, L., Wei, Y., & Wang, X. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180126 · Cited by 71 · see citing works

Peripherally derived angiotensin converting enzyme-enhanced macrophages alleviate Alzheimer-related disease

Koronyo‐Hamaoui, M., Sheyn, J., Hayden, E. Y., Li, S., Fuchs, D.-T. S., Regis, G. C., Lopes, D. H. J., Black, K. L., Bernstein, K. E., Teplow, D. B., et al. (2019) · Brain · doi:10.1093/brain/awz364 · Cited by 70 · see citing works

Targeting Tau Hyperphosphorylation via Kinase Inhibition: Strategy to Address Alzheimer's Disease

Naqvi, A. A. T., Hasan, G. M., & Hassan, M. I. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200106125910 · Cited by 70 · see citing works

miR‐181a negatively modulates synaptic plasticity in hippocampal cultures and its inhibition rescues memory deficits in a mouse model of Alzheimer’s disease

Rodríguez‐Ortiz, C. J., Prieto, G. A., Martini, A. C., Forner, S., Trujillo‐Estrada, L., LaFerla, F. M., Baglietto‐Vargas, D., Cotman, C. W., & Kitazawa, M. (2020) · Aging Cell · doi:10.1111/acel.13118 · Cited by 67 · see citing works

Tryptophan metabolites modify brain Aβ peptide degradation: A role in Alzheimer's disease?

Maitre, M., Klein, C., Patte-Mensah, C., & Mensah-Nyagan, A. (2020) · Progress in neurobiology · doi:10.1016/j.pneurobio.2020.101800 · Cited by 63 · see citing works

Safety and efficacy of Melissa officinalis extract containing rosmarinic acid in the prevention of Alzheimer’s disease progression

Noguchi‐Shinohara, M., Ono, K., Hamaguchi, T., Nagai, T., Kobayashi, S., Komatsu, J., Samuraki-Yokohama, M., Iwasa, K., Yokoyama, K., Nakamura, H., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-73729-2 · Cited by 67 · see citing works

Time-dependent reversal of synaptic plasticity induced by physiological concentrations of oligomeric Aβ42: an early index of Alzheimer’s disease

Koppensteiner, P., Trinchese, F., Fà, M., Puzzo, D., Gulisano, W., Yan, S., Poussin, A., Liu, S., Orozco, I. J., Dale, E., et al. (2016) · Scientific Reports · doi:10.1038/srep32553 · Cited by 64 · see citing works

Inhibition of Aβ aggregates in Alzheimer’s disease by epigallocatechin and epicatechin-3-gallate from green tea

Chen, T., Yang, Y., Zhu, S., Lu, Y., Zhu, L., Wang, Y., & Wang, X. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104382 · Cited by 64 · see citing works

Electrocatalysis of Copper Sulfide Nanoparticle-Engineered Covalent Organic Frameworks for Ratiometric Electrochemical Detection of Amyloid-β Oligomer

Chen, Y., Wang, S., Ren, J., Zhao, H., Cui, M., Li, N., Li, M. C., & Zhang, C. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c01602 · Cited by 65 · see citing works

Amyloid Beta Oligomers Target to Extracellular and Intracellular Neuronal Synaptic Proteins in Alzheimer's Disease

Ding, Y. J., Zhao, J., Zhang, X., Wang, S., Viola, K. L., Chow, F. E., Zhang, Y., Lippa, C. F., Klein, W. L., & Gong, Y. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01140 · Cited by 65 · see citing works

Decoding the synaptic dysfunction of bioactive human AD brain soluble Aβ to inspire novel therapeutic avenues for Alzheimer’s disease

Li, S., Jin, M., Liu, L., Dang, Y., Ostaszewski, B. L., & Selkoe, D. J. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0626-x · Cited by 64 · see citing works

Neurochemical correlation between major depressive disorder and neurodegenerative diseases

Réus, G. Z., Titus, S. E., Abelaira, H. M., Freitas, S. M., Tuon, T., Quevedo, J., & Budni, J. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.06.027 · Cited by 63 · see citing works

The Implication of the Brain Insulin Receptor in Late Onset Alzheimer’s Disease Dementia

Folch, J., Ettcheto, M., Busquets, O., Sánchez‐López, E., Castro-Torres, R. D., Verdaguer, E., Manzine, P. R., Poor, S. R., García, M. L., Olloquequi, J., et al. (2018) · Pharmaceuticals · doi:10.3390/ph11010011 · Cited by 63 · see citing works

Lecanemab demonstrates highly selective binding to Aβ protofibrils isolated from Alzheimer's disease brains

Johannesson, M., Söderberg, L., Zachrisson, O., Fritz, N., Kylefjord, H., Gkanatsiou, E., Button, E. B., Svensson, A.-S., Rachalski, A., Nygren, P., et al. (2024) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2024.103949 · Cited by 66 · see citing works

A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects

Lues, I., Weber, F., Meyer, A., Uli, B., Hoffmann, T., Kühn‐Wache, K., Manhart, S., Heiser, U. F., Pokorny, R., Chiesa, J., et al. (2015) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2015.08.002 · Cited by 62 · see citing works

Ginnalin A Inhibits Aggregation, Reverses Fibrillogenesis, and Alleviates Cytotoxicity of Amyloid β(1–42)

Fan, Q., Liu, Y., Wang, X., Zhang, Z., Fu, Y., Liu, L., Wang, P., Ma, H., Ma, H., Seeram, N. P., et al. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00673 · Cited by 62 · see citing works

Supramolecular Copolymers of Peptides and Lipidated Peptides and Their Therapeutic Potential

Qiu, R., Sasselli, I. R., Álvarez, Z., Sai, H., Ji, W., Palmer, L. C., & Stupp, S. I. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c00433 · Cited by 61 · see citing works

Association between increased levels of amyloid-β oligomers in plasma and episodic memory loss in Alzheimer’s disease

Meng, X. W., Li, T., Wang, X., Lv, X., Sun, Z., Zhang, J., Feng, S., Kang, S., Kim, S., An, S. S. A., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0535-7 · Cited by 63 · see citing works

Effects of methionine intake on cognitive function in mild cognitive impairment patients and APP/PS1 Alzheimer's Disease model mice: Role of the cystathionine-β-synthase/H2S pathway

Xi, Y., Zhang, Y., Zhou, Y., Liu, Q., Chen, X., Liu, X., Grune, T., Shi, L. S., Hou, M., & Liu, Z. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102595 · Cited by 62 · see citing works

BACE1 inhibitory activity and molecular docking analysis of meroterpenoids from Sargassum serratifolium

Seong, S. H., Ali, M. Y., Kim, H., Jung, H. A., & Choi, J. S. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.05.033 · Cited by 61 · see citing works

Cellular Receptors of Amyloid β Oligomers (AβOs) in Alzheimer’s Disease

Mroczko, B., Groblewska, M., Litman-Zawadzka, A., Kornhuber, J., & Lewczuk, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071884 · Cited by 97 · see citing works

Synaptotoxic Amyloid-β Oligomers: A Molecular Basis for the Cause, Diagnosis, and Treatment of Alzheimer's Disease?

Klein William, L. (2013) · Advances in Alzheimer's disease · doi:10.3233/978-1-61499-154-0-49

Soluble amyloid-β oligomers as synaptotoxins leading to cognitive impairment in Alzheimer’s disease

Ferreira, S. T., Lourenco, M. V., Oliveira, M. M., & De Felice, F. G. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00191 · Cited by 373 · see citing works

Amyloid β oligomers (AβOs) in Alzheimer’s disease

Mroczko, B., Groblewska, M., Litman‐Zawadzka, A., Kornhuber, J., & Lewczuk, P. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1820-x · Cited by 146 · see citing works

Alzheimer’s disease as oligomeropathy

Ono, K. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2017.08.010 · Cited by 129 · see citing works